PURPOSE: To determine the primary sources and secondary complications of Staphylococcus aureus bacteremia (SAB) in cancer patients, as well as predictors of outcome in cancer patients with SAB. PATIENTS AND METHODS: Fifty-two patients at Duke University Medical Center met entry criteria between September 1994 and December 1996 for this prospective cohort study involving hospitalized nonneutropenic adult cancer patients with SAB. All subjects were observed throughout initial hospitalization and were evaluated again at 6 and 12 weeks or until death. RESULTS: SAB was intravascular device-related in 42%, tissue infection-related (TIR) in 44%, and unidentifiable focus-related (UFR) in 13%. Seventeen patients (33%) were found to have metastatic infections or conditions, with eight (15%) developing infectious endocarditis (IE). Patients with TIR bacteremia were less likely than other patients to develop IE (4% v 24%, P =.06). The overall mortality rate was 38%, the SAB-related mortality rate was 15%, and the rate of SAB relapse was 12%. Methicillin resistance was not associated with adverse outcome. Inability to identify a point of entry (UFR bacteremia), however, was associated with a higher overall mortality rate (100% v 24%, P =.0006). Furthermore, a 72-hour surveillance blood culture positive for organisms was associated with an increased incidence of IE (P =.0006), metastatic infections or conditions (P =.0002), SAB relapse (P =.038), and SAB-related death (P =.038). CONCLUSION: SAB in cancer patients is associated with significant morbidity from frequent metastatic infections or conditions including IE, as well as considerable mortality. Unknown initial infection site and 72-hour surveillance cultures positive for organisms were predictive of a complicated course and poor final outcome.
PURPOSE: To determine the primary sources and secondary complications of Staphylococcus aureus bacteremia (SAB) in cancerpatients, as well as predictors of outcome in cancerpatients with SAB. PATIENTS AND METHODS: Fifty-two patients at Duke University Medical Center met entry criteria between September 1994 and December 1996 for this prospective cohort study involving hospitalized nonneutropenic adult cancerpatients with SAB. All subjects were observed throughout initial hospitalization and were evaluated again at 6 and 12 weeks or until death. RESULTS:SAB was intravascular device-related in 42%, tissue infection-related (TIR) in 44%, and unidentifiable focus-related (UFR) in 13%. Seventeen patients (33%) were found to have metastatic infections or conditions, with eight (15%) developing infectious endocarditis (IE). Patients with TIR bacteremia were less likely than other patients to develop IE (4% v 24%, P =.06). The overall mortality rate was 38%, the SAB-related mortality rate was 15%, and the rate of SAB relapse was 12%. Methicillin resistance was not associated with adverse outcome. Inability to identify a point of entry (UFR bacteremia), however, was associated with a higher overall mortality rate (100% v 24%, P =.0006). Furthermore, a 72-hour surveillance blood culture positive for organisms was associated with an increased incidence of IE (P =.0006), metastatic infections or conditions (P =.0002), SAB relapse (P =.038), and SAB-related death (P =.038). CONCLUSION:SAB in cancerpatients is associated with significant morbidity from frequent metastatic infections or conditions including IE, as well as considerable mortality. Unknown initial infection site and 72-hour surveillance cultures positive for organisms were predictive of a complicated course and poor final outcome.
Authors: G Fätkenheuer; M Preuss; B Salzberger; N Schmeisser; O A Cornely; H Wisplinghoff; H Seifert Journal: Eur J Clin Microbiol Infect Dis Date: 2004-02-25 Impact factor: 3.267
Authors: M L H Cuijpers; F J Vos; C P Bleeker-Rovers; P F M Krabbe; P Pickkers; A P J van Dijk; G J A Wanten; P D Sturm; W J G Oyen; B J Kullberg Journal: Eur J Clin Microbiol Infect Dis Date: 2007-02 Impact factor: 3.267
Authors: Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Ashok Srinivasan; Steven E Seifried; Liang Zhu; Deo K Srivastava; Rosalie Perkins; Jerry L Shenep; Matthew J Bankowski; Randall T Hayden Journal: Pediatr Blood Cancer Date: 2010-09-09 Impact factor: 3.167
Authors: Cesar A Virgen; Viswanath R Belum; Mini Kamboj; Shari B Goldfarb; Victoria S Blinder; Ayca Gucalp; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2018-03 Impact factor: 11.527
Authors: Zoe Loh; Ortis Estacio; Andrew Grigg; Natasha E Holmes; Geoff Chong; Eliza A Hawkes Journal: Support Care Cancer Date: 2018-03-21 Impact factor: 3.603
Authors: Coralia N Mihu; Jenifer Schaub; Sandra Kesh; Ann Jakubowski; Kent Sepkowitz; Eric G Pamer; Genovefa A Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2008-12 Impact factor: 5.742
Authors: Patrick G Morris; Tidi Hassan; Mairead McNamara; Astrid Hassan; Rebecca Wiig; Liam Grogan; Oscar S Breathnach; Edmond Smyth; Hilary Humphreys Journal: Support Care Cancer Date: 2008-02-15 Impact factor: 3.603